Indication

Monotherapy as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the Union for International Cancer Control (UICC)/ American Joint Committee on Cancer (AJCC) - staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells (TC) and whose disease has not progressed following platinum-based adjuvant chemotherapy.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2492
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
08 August 2022
SMC meeting date:
05 July 2022
Patient group submission deadline:
06 June 2022